Article from https://www.independent.co.uk/news/eu-regulator-starts-safety-review-coronavirus-drug-eu-european-medicines-agency-regulator-patients-remdesivir-b749229.html also the guardian is reporting this.
Reminder that early tests of MPL show it to be notably similar to the inhibition demonstrated for remdesivir but with a strong safety profile behind it.
^ From company ann 9th September.
PAA is currently evaluating the use of MPL for COVID in EUROPE. I hope the board is at least reaching out to the EMA with some early data and getting MPL on their radar.
Article from...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.5¢ | 19.5¢ | $459.0K | 2.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 103700 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 127225 | 3 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |